Project Details
Description
The INFRAFRONTIER RI integrates European Mouse Clinics and the European Mouse Mutant Archive with the common goal to ensure access to mouse models for basic research of human health and disease, and to translate this knowledge into therapeutic approaches for the benefit of the European society.
The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is strategically responding to the INFRADEV3 call with aligned objectives to advance the long-term sustainability which are 1) development of business models and a stable legal framework; 2) raise awareness of the INFRAFRONTIER RI; 3) provide bespoke services aligned with user demands; 4) promote best practices in mouse phenogenomics; 5) enhance robustness of the INFRAFRONTIER IT infrastructure and use of the EMMA strain resource; and 6) improve business processes. Towards achieving these objectives key INFRAFRONTIER2020 project deliverables are:
• INFRAFRONTIER Business Plan2.0 and business models for all services
• Stable legal framework built on the INFRAFRONTIER legal entity
• INFRAFRONTIER annual stakeholder conferences
• Customised mouse model and secondary phenotyping pilot services
• INFRAFRONTIER advanced training schools in mouse phenogenomics
• Reengineered EMMA Database2.0 system
• Annotated mouse models of human diseases
• Quality management system for the legal entity
INFRAFRONTIER2020 will 1) enhance the sustainable operation of the INFRAFRONTIER RI; 2) continue to structure the ERA, 3) foster innovation, and 4) address major societal challenges in human health by customised service pilots supporting research into common and rare diseases. A sustainable INFRAFRONTIER RI will ensure the quality of deposited mice and support the reproducibility of biological results. Outreach efforts will raise awareness of resources and services and facilitate sustainable engagement with industry and global consortia such as the International Mouse Phenotyping Consortium
The expanded INFRAFRONTIER2020 network, coordinated by the INFRAFRONTIER GmbH, includes 3 SMEs and is strategically responding to the INFRADEV3 call with aligned objectives to advance the long-term sustainability which are 1) development of business models and a stable legal framework; 2) raise awareness of the INFRAFRONTIER RI; 3) provide bespoke services aligned with user demands; 4) promote best practices in mouse phenogenomics; 5) enhance robustness of the INFRAFRONTIER IT infrastructure and use of the EMMA strain resource; and 6) improve business processes. Towards achieving these objectives key INFRAFRONTIER2020 project deliverables are:
• INFRAFRONTIER Business Plan2.0 and business models for all services
• Stable legal framework built on the INFRAFRONTIER legal entity
• INFRAFRONTIER annual stakeholder conferences
• Customised mouse model and secondary phenotyping pilot services
• INFRAFRONTIER advanced training schools in mouse phenogenomics
• Reengineered EMMA Database2.0 system
• Annotated mouse models of human diseases
• Quality management system for the legal entity
INFRAFRONTIER2020 will 1) enhance the sustainable operation of the INFRAFRONTIER RI; 2) continue to structure the ERA, 3) foster innovation, and 4) address major societal challenges in human health by customised service pilots supporting research into common and rare diseases. A sustainable INFRAFRONTIER RI will ensure the quality of deposited mice and support the reproducibility of biological results. Outreach efforts will raise awareness of resources and services and facilitate sustainable engagement with industry and global consortia such as the International Mouse Phenotyping Consortium
| Acronym | INFRAFRONTIER |
|---|---|
| Status | Finished |
| Effective start/end date | 1/01/17 → 31/12/21 |
Collaborative partners
- Centre Européen pour la Recherche en Biologie et Médecine - Groupement d'Intérêt Economique (Project partner)
- National Research Council of Italy (Project partner)
- French National Centre for Scientific Research (CNRS) (Project partner)
- Spanish National Research Council (CSIC) (Project partner)
- European Molecular Biology Laboratory (EMBL) (Project partner)
- Biomedical Sciences Research Center "Alexander Fleming" (BSRC Al. Fleming) (Project partner)
- Calouste Gulbenkian Foundation (Project partner)
- USTAV MOLEKULARNI GENETIKY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE (Project partner)
- Genome Research Ltd. (Project partner)
- Helmholtz-Zentrum fuer Infektionsforschung GmbH (Project partner)
- French National Institute of Health and Medical Research (INSERM) (Project partner)
- Pasteur Institute (Project partner)
- The Bodin Karolinska Institutet (Project partner)
- Hannover Medical School (Project partner)
- Medical Research Council (MRC) (Project partner)
- Stichtint het nederlands Kanker Institut (Project partner)
- Toronto Center for Phenogenomics Inc. (Project partner)
- Tel Aviv University (Project partner)
- TSE SYSTEMS GMBH (Project partner)
- University of Oulu (Project partner)
- University of Sheffield (Project partner)
- Veterinaermedizinische Universitaet Wien (Project partner)
- Ayoxxa biosystems (Project partner)
- BIOMEDCODE S.A. (Project partner)
- Infrafrontier GmbH (Project partner)
- University of Copenhagen (Project partner)
- Academisch ziekenhuis groningen (Project partner)
- Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (Project partner)
Funding
- European Commission (EC): €4,955,880.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.